PriMera Scientific Medicine and Public Health (ISSN: 2833-5627)

Research Article

Volume 2 Issue 5

A Look of the Novel Coronavirus (COVID-19) in Terms of Pathogenesis and Global Outbreak

Muhammad Akram, Anmole Razzaq*, Abid Rashid, Hafiz Saad Ahmad, Abdul Wadood Chishti, Umme Laila, Momina Iftikhar, Rida Zainab, Muhammad Talha Khalil and Fethi Ahmet Ozdemir

March 29, 2023

View PDF

Abstract

In the month of December 2019, Wuhan which is a city of Hubei, state of China suffered an unusual outburst of pneumonia of unclear origin. The causative agent was described as a novel coronavirus, which the WHO (World Health Organization) designated as COVID-19. Coronavirus-19 is initiated by a β-coronavirus called SARS-Covid-2 that presents itself as pneumonia and disturbs the lower respiratory tract in individuals. It's related to SARS and MERS. Covid-19 continues to spread amid worldwide isolation and quarantine attempts. We summaries the existing state of awareness concerning COVID-19 as a response to this global outbreak.

Keywords: Coronavirus (COVID-19); Pathogenesis; Global Outbreak

References

  1. Bogoch A., et al. “Pneumonia of unknown etiology in wuhan, China: potential for international spread via commercial air travel”. J. Trav. Med 27.2 (2020).
  2. Lu H, Stratton CW and Tang YW. “Outbreak of pneumonia of unknown etiology in wuhan China: the mystery and the miracle”. J. Med. Virol 92.4 (2020): 401-402.
  3. S Zhao., et al. “Preliminary estimation of the basic reproduction number of novel coronavirus (2019-nCoV): in China, from 2019 to 2020: a data-driven analysis in the early phase of the outbreak”. Int. J. Infect. Dis.: IJID : Off. Publ. Int. Soc. Infect. Dis 92 (2020): 214-217.
  4. Du Toit. “Outbreak of a novel coronavirus”. Nat. Rev. Microbiol 18 (2020): 123.
  5. LL Ren., et al. “Identification of a novel coronavirus causing severe pneumonia in human: a descriptive study”. Chinese Med J (2020).
  6. C Huang., et al. “Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China”. Lancet 395.10223 (2020): 497-506.
  7. H Lu. “Drug treatment options for the 2019-new coronavirus (2019-nCoV)”. Biosci. Trends (2020).
  8. W Wang, J Tang and F Wei. “Updated understanding of the outbreak of 2019 novel coronavirus (2019-nCoV): in Wuhan, China”. J. Med. Virol 92.4 (2020): 441-447.
  9. H Nishiura., et al. “The extent of transmission of novel coronavirus in wuhan”. China, 2020, J. Clin. Med 9 (2020).
  10. M Bassetti, A Vena and D Roberto Giacobbe. “The Novel Chinese Coronavirus (2019-nCoV): Infections: challenges for fighting the storm”. Eur. J. Clin. Invest (2020): e13209.
  11. ML Holshue., et al. “First case of 2019 novel coronavirus in the United States”. N. Engl. J. Med (2020).
  12. Q Li., et al. “Early transmission dynamics in wuhan, China, of novel coronavirus-infected pneumonia”. N. Engl. J. Med (2020).
  13. WG Carlos., et al. “Novel wuhan (2019-nCoV): coronavirus”. Am. J. Respir. Crit. Care Med 201.4 (2020): 7-8.
  14. J Lei., et al. “CT imaging of the 2019 novel coronavirus (2019-nCoV): pneumonia”. Radiology (2020).
  15. Assiri JA., et al. “Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study”. Lancet Infect. Dis 13 (2013): 752-761.
  16. N Lee., et al. “A major outbreak of severe acute respiratory syndrome in Hong Kong”. N. Engl. J. Med 348 (2003): 1986-1994.
  17. LT Phan., et al. “Importation and human-to-human transmission of a novel coronavirus in Vietnam”. N. Engl. J. Med (2020).
  18. W Ji., et al. “Homologous recombination within the spike glycoprotein of the newly identified coronavirus may boost cross-species transmission from snake to human”. J. Med. Virol 92.4 (2020): 433-440.
  19. R Lu., et al. “Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding”. Lancet 395.10224 (2020): 565-574.
  20. Y Wan., et al. “Receptor recognition by novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS”. J. Virol (2020).
  21. P Wu., et al. “Real-time tentative assessment of the epidemiological characteristics of novel coronavirus infections in Wuhan, China”. as at 22 January 2020 Euro Surveill 25 (2020).
  22. JA Jaimes., et al. “Whittaker, A tale of two viruses: the distinct spike glycoproteins of feline coronaviruses”. Viruses 12 (2020).
  23. DS Hui., et al. “The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health - the latest 2019 novel coronavirus outbreak in Wuhan, China”. Int. J. Infect. Dis 91 (2020): 264-266.
  24. J Cui, F Li and ZL Shi. “Origin and evolution of pathogenic coronaviruses”. Nat. Rev. Microbiol 17 (2019): 181-192.
  25. N Zhu., et al. “A novel coronavirus from patients with pneumonia in China”. N. Engl. J. Med 382 (2019): 727-733.
  26. P Zhou., et al. “A pneumonia outbreak associated with a new coronavirus of probable bat origin”. Nature (2020).
  27. E de Wit., et al. “SARS and MERS: recent insights into emerging coronaviruses”. Nat. Rev. Microbiol 14 (2016): 523-534.
  28. JT Wu, K Leung and GM Leung. “Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study”. Lancet (2020).
  29. S Su., et al. “Epidemiology, Genetic recombination, and pathogenesis of coronaviruses”. Trends Microbiol 24 (2016): 490-502.
  30. S Perlman and J Netland. “Coronaviruses post-SARS: update on replication and pathogenesis”. Nat. Rev. Microbiol 7 (2009): 439-450.
  31. R Lu., et al. “Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding”. Lancet (2020).
  32. AR Fehr and S Perlman. “Coronaviruses: an overview of their replication and pathogenesis”. Methods Mol. Biol 1282 (2015): 1-23.
  33. PS Masters. “The molecular biology of coronaviruses”. Adv. Virus Res 66 (2006): 193-292.
  34. K Knoops., et al. “SARS-coronavirus replication is supported by a reticulovesicular network of modified endoplasmic reticulum”. PLoS Biol 6 (2008).
  35. W Li., et al. “Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus”. Nature 426 (2003): 450-454.
  36. XY Ge., et al. “Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor”. Nature 503 (2013): 535-538.
  37. Chinese SARS Molecular Epidemiology Consortium, Chinese Molecular evolution of the SARS coronavirus during the course of the SARS epidemic in China, Science 303 (2004): 1666-1669.
  38. VS Raj., et al. “Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC”. Nature 495 (2013): 251-254.
  39. Barlan J Zhao., et al. “Receptor variation and susceptibility to Middle East respiratory syndrome coronavirus infection”. J. Virol 88 (2014): 4953-4961.
  40. C Huang., et al. “Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China”. Lancet (2020).
  41. JS Peiris, Y Guan and KY Yuen. “Severe acute respiratory syndrome”. Nat. Med 10 (2004): S88-S97.
  42. F Wu., et al. “A new coronavirus associated with human respiratory diseases in China”. Nature (2020).
  43. SA Jeffers., et al. “CD209L (L-SIGN): is a receptor for severe acute respiratory syndrome coronavirus”. Proc. Natl. Acad. Sci. U.S.A 101 (2004): 15748-15753.
  44. G Simmons., et al. “Characterization of severe acute respiratory syndrome-associated coronavirus (SARS-CoV): spike glycoprotein-mediated viral entry”. Proc. Natl. Acad. Sci. U.S.A 101 (2004): 4240-4245.
  45. S Belouzard, VC Chu and GR Whittaker. “Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites”. Proc. Natl. Acad. Sci. U.S.A 106 (2009): 5871-5876.
  46. JK Millet and GR Whittaker. “Host cell entry of Middle East respiratory syndrome coronavirus after two-step, furin-mediated activation of the spike protein”. Proc. Natl. Acad. Sci. U.S.A 111 (2014): 15214-15219.
  47. H Wang., et al. “SARS coronavirus entry into host cells through a novel clathrin- and caveolae-independent endocytic pathway”. Cell Res 18 (2008): 290-301.
  48. K Kuba., et al. “Trilogy of ACE2: a peptidase in therenin-angiotensin system, a SARS receptor, and a partner for amino acid transporters”. Pharmacol. Ther 128 (2010): 119-128.
  49. J Liu., et al. “Novel immunodominant peptide presentation strategy: a featured HLA-A*2402-restricted cytotoxic T-lymphocyte epitope stabilized by intrachain hydrogen bonds from severe acute respiratory syndrome coronavirus nucleocapsid protein”. J. Virol 84 (2010): 11849-11857.
  50. N Keicho., et al. “Association of human leukocyte antigen class II alleles with severe acute respiratory syndrome in the Vietnamese population”. Hum. Immunol 70 (2009): 527-531.
  51. YM Chen., et al. “Epidemiological and genetic correlates of severe acute respiratory syndrome coronavirus infection in the hospital with the highest nosocomial infection rate in Taiwan in 2003”. J. Clin. Microbiol 44 (2006): 359-365.
  52. SF Wang., et al. “Human-leukocyte antigen class I Cw 1502 and class II DR 0301 genotypes are associated with resistance to severe acute respiratory syndrome (SARS): infection”. Viral Immunol 24 (2011): 421-426.
  53. AH Hajeer., et al. “Association of human leukocyte antigen class II alleles with severe Middle East respiratory syndrome-coronavirus infection”. Ann. Thorac. Med 11 (2016): 211-213.
  54. X Tu., et al. “Functional polymorphisms of the CCL2 and MBL genes cumulatively increase susceptibility to severe acute respiratory syndrome coronavirus infection”. J. Infect 71 (2015): 101-109.
  55. G Li, X Chen and A Xu. “Profile of specific antibodies to the SARS-associated coronavirus”. N. Engl. J. Med 349 (2003): 508-509.
  56. Z Xu., et al. “Pathological findings of COVID-19 associated with acute respiratory distress syndrome”. Lancet Resp. Med (2020).
  57. YY Fan., et al. “Characterization of SARS-CoV-specific memory T cells from recovered individuals 4 years after infection”. Arch. Virol 154 (2009): 1093-1099.
  58. F Tang., et al. “Lack of peripheral memory B cell responses in recovered patients with severe acute respiratory syndrome: a six-year follow up follow up study”. J. Immunol 186 (2011): 7264-7268.
  59. J Zhao., et al. “Rapid generation of a mouse model for Middle East respiratory syndrome”. Proc. Natl. Acad. Sci. U.S.A 111 (2014): 4970-4975.
  60. AE Williams and RC Chambers. “The mercurial nature of neutrophils: still an enigma in ARDS?”. Am. J. Physiol. Lung Cell Mol. Physiol 306 (2014): L217-L230.
  61. R Channappanavar and S Perlman. “Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology”. Semin. Immunopathol 39 (2017): 529-539.
  62. MJ Cameron., et al. “Human immunopathogenesis of severe acute respiratory syndrome (SARS)”. Virus Res 133 (2008)13-19.
  63. CK Min., et al. “Comparative and kinetic analysis of viral shedding and immunological responses in MERS patients representing a broad spectrum of disease severity”. Sci. Rep 6 (2016): 25359.
  64. EJ Snijder., et al. “Ultrastructure and origin of membrane vesicles associated with the severe acute respiratory syndrome coronavirus replication complex”. J. Virol 80 (2006): 5927-5940.
  65. R Channappanavar., et al. “Dysregulated type I interferon and inflammatory monocyte-macrophage responses cause lethal pneumonia in SARS-CoV-infected mice”. Cell Host Microbe 19 (2016): 181-193.
  66. R Channappanavar., et al. “IFN-I response timing relative to virus replication determines MERS coronavirus infection outcomes”. J. Clin. Invest 130 (2019): 3625-3639.
  67. D Niemeyer., et al. “Middle East respiratory syndrome coronavirus accessory protein 4a is a type I interferon antagonist”. J. Virol 87 (2013): 12489-12495.
  68. Y Yang., et al. “The structural and accessory proteins M, ORF 4a, ORF 4b, and ORF 5 of Middle East respiratory syndrome coronavirus (MERS-CoV): are potent interferon antagonists”. Protein Cell 4 (2013): 951-961.
  69. VD Menachery., et al. “MERS-CoV and H5N1 influenza virus antagonize antigen presentation by altering the epigenetic landscape”. Proc. Natl. Acad. Sci. U.S.A 115 (2018): E1012-E1021.
  70. M Corman., et al. “Detection of 2019 novel coronavirus (2019-nCoV): by real-time RT-PCR”. Euro Surveill 25 (2020).
  71. H Lu, CW Stratton and Y Tang. “Outbreak of pneumonia of unknown etiology in wuhan China: the mystery and the miracle”. J. Med. Virol (2020).
  72. World Health Organization, WHO Director-General’s Remarks at the Media Briefingon 2019-nCoV (2020).
  73. N Chen., et al. “Epidemiological and clinical characteristics of 99cases of 2019 novel coronavirus pneumonia in Wuhan”. China: a descriptive study,Lancet (2020).
  74. D Wang., et al. “Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in wuhan, China”. J. Am. Med.Assoc (2020).
  75. World Health Organization, Novel Coronavirus (2019-nCoV), Situation Report – 12 (2020).
  76. Wellcome, Sharing Research Data and Findings Relevant to the Novel Coronavirus(nCoV): Outbreak (2020).
  77. European Commission, Coronavirus: EU Mobilises €10 Million for Research (2020).
  78. Verdict Medical Devices, Co-Diagnostics Launches RUO Test for New Coronavirus (2020).
  79. Verdict Medical Devices, Primerdesign Launches Molecular Test for NewCoronavirus (2020).
  80. BBC, Coronavirus: UK Donates £20m to Speed up Vaccine (2020).
  81. The White House, Proclamation on Suspension of Entry as Immigrants and Nonimmigrants of Persons Who Pose a Risk of Transmitting 2019 NovelCoronavirus (2020).
  82. BBC, Coronavirus: Hong Kong Hospital Staff Strike to Demand Closure of China Border (2020).
  83. BBC, Coronavirus: China to Pump Billions into Economy amid Growth Fears (2020).
  84. Bloomberg Businessweek Coronavirus Is More Dangerous for the Global Economy than SARS (2020).
  85. Reuters Instant View: China's Economic Growth Slows to 6.1% in 2019, Near 30-year Low (2020).
  86. As Wuhan Coronavirus Drags on Chinese Markets, the World Economy Braces for a Slowdown (2020).
  87. Brookings Global Manufacturing Scorecard: How the US Compares to 18 Other Nations (2018).
  88. China's Oil Imports Are Most World's Ever Seen and Still Growing Financial Times China’s Xi Jinping knew of coronavirus earlier than first thought (2020).